IL96039A0 - Injectable formulation for lipophilic drug - Google Patents

Injectable formulation for lipophilic drug

Info

Publication number
IL96039A0
IL96039A0 IL96039A IL9603990A IL96039A0 IL 96039 A0 IL96039 A0 IL 96039A0 IL 96039 A IL96039 A IL 96039A IL 9603990 A IL9603990 A IL 9603990A IL 96039 A0 IL96039 A0 IL 96039A0
Authority
IL
Israel
Prior art keywords
injectable formulation
lipophilic drug
lipophilic
drug
injectable
Prior art date
Application number
IL96039A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL96039A0 publication Critical patent/IL96039A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL96039A 1989-10-30 1990-10-17 Injectable formulation for lipophilic drug IL96039A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42880389A 1989-10-30 1989-10-30

Publications (1)

Publication Number Publication Date
IL96039A0 true IL96039A0 (en) 1991-07-18

Family

ID=23700467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL96039A IL96039A0 (en) 1989-10-30 1990-10-17 Injectable formulation for lipophilic drug

Country Status (8)

Country Link
EP (1) EP0426029A1 (ja)
JP (1) JPH03169807A (ja)
KR (1) KR910007509A (ja)
AU (1) AU6461090A (ja)
CA (1) CA2028604A1 (ja)
IE (1) IE903718A1 (ja)
IL (1) IL96039A0 (ja)
PT (1) PT95716A (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023241A1 (de) * 1990-07-21 1992-01-23 Knoll Ag Stabile wirkstoff-formulierung
DE4234225A1 (de) * 1992-10-10 1994-04-14 Roehm Pharma Gmbh Stabile topische Formulierungen mit gutem Wirkstoff-Freisetzungsvermögen enthaltend mindestens ein lipophilisiertes Makrolidantibiotikum
DE4305003A1 (de) * 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
DK0990440T3 (da) * 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
AR043071A1 (es) * 1997-10-31 2005-07-20 Abbott Lab Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ATE521355T1 (de) 2004-05-19 2011-09-15 Los Angeles Biomed Res Inst Verwendung eines detergens zur nicht- chirurgischen entfernung von fett
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
TWI691341B (zh) 2013-11-08 2020-04-21 日商活效製藥股份有限公司 含有巨環內酯系抗菌劑之奈米微粒子之水性懸濁液劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4707470A (en) * 1985-05-17 1987-11-17 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
NZ232865A (en) * 1989-03-21 1992-07-28 Hoffmann La Roche A mixed-micelle solution comprising a micelle former and an immunomodulator

Also Published As

Publication number Publication date
CA2028604A1 (en) 1991-05-01
KR910007509A (ko) 1991-05-30
AU6461090A (en) 1991-05-02
PT95716A (pt) 1991-09-13
IE903718A1 (en) 1991-05-08
EP0426029A1 (en) 1991-05-08
JPH03169807A (ja) 1991-07-23

Similar Documents

Publication Publication Date Title
EP0428268A3 (en) Pharmaceutical phenylpyridone derivatives
EP0408496A3 (en) Solid dosage form for pharmaceutical substances
IL96039A0 (en) Injectable formulation for lipophilic drug
GB8916682D0 (en) Pharmaceutical compounds
GB8917959D0 (en) Pharmaceutical formulation
GB2232891B (en) Pharmaceutical composition
CS343490A3 (en) Pharmaceutical
IL93143A0 (en) Transdermal drug delivery composition
GB8830405D0 (en) Pharmaceutical formulation
GB8919593D0 (en) Pharmaceutical formulation
ZA902089B (en) Pharmaceutical formulation
GB8902809D0 (en) Pharmaceutical formulation
GB8923046D0 (en) Pharmaceutical formulation
GB8919596D0 (en) Pharmaceutical formulation
GB8919594D0 (en) Pharmaceutical formulation
GB8909924D0 (en) Pharmaceutical formulation
GB8919592D0 (en) Pharmaceutical formulation
IE893119L (en) Pharmaceutical formulation
GB8926945D0 (en) Pharmaceutical formulation
GB8904040D0 (en) Pharmaceutical compounds
GB8920738D0 (en) Pharmaceutical compounds
GB8911196D0 (en) Pharmaceutical compounds
GB8906262D0 (en) Pharmaceutical compounds
CS275316B2 (en) Drug for hepatic arrosion
GB8901158D0 (en) Administering drugs